Mortality rates are increased in acromegaly. Previous studies have shown that growth hormone and insulin-like growth factor 1 levels, male gender, age, hypertension, delayed diagnosis and prior pituitary radiotherapy are independent predictors of increased mortality. A new study by Sherlock et al. now adds adrenal insufficiency and hydrocortisone replacement dose to the list of independent predictors of acromegaly-associated mortality.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-term safety of gamma knife radiosurgery (SRS) for acromegaly
Pituitary Open Access 26 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89–95 (2008).
Kauppinen-Makelin, R. et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081–4086 (2005).
Sherlock, M. et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 4216–4223 (2009).
Ayuk, J. et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89, 1613–1617 (2004).
Tomlinson, J. W. et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357, 425–431 (2001).
Mestron, A. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151, 439–446 (2004).
Bex, M. et al. AcroBel—the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 399–409 (2007).
Bergthorsdottir, R., Leonsson-Zachrisson, M., Oden, A. & Johannsson, G. Premature mortality in patients with Addison's disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006).
Bensing, S. et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin. Endocrinol. (Oxf.) 69, 697–704 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ben-Shlomo, A. Predictors of acromegaly-associated mortality. Nat Rev Endocrinol 6, 67–69 (2010). https://doi.org/10.1038/nrendo.2009.267
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.267
This article is cited by
-
Long-term safety of gamma knife radiosurgery (SRS) for acromegaly
Pituitary (2021)
-
Application of pluripotent stem cells for treatment of human neuroendocrine disorders
Cell and Tissue Research (2019)
-
Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study
Pituitary (2015)
